Ovarian Cancer Market

Ovarian Cancer Market is segmented By Type (Epithelial ovarian cancer, Germ cell ovarian cancer, Stromal cell ovarian cancer, Small cell ovarian cancer), By Treatment Type (Targeted Therapy, Surgery, Chemotherapy, Immunotherapy, Others), By Diagnosis type (Blood tests, Imaging tests, Laparoscopy, Colonoscopy, Others), By Drug class (PARP Inhibitors, Angiogenesis Inhibitors, PD-L1 Inhibitors), By End-user (Hospitals, Clinics, Cancer centers, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

 

Ovarian Cancer Market was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 16% during the forecast period (2022-2029).

Ovarian Cancer Market Scope

Metrics	Details
Market CAGR	16%
Segments Covered	By Type, By Treatment Type, By Diagnosis Type, By Drug Class, and By Region
Report Insights Covered	Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
Fastest Growing Region	Asia Pacific
Largest Market Share	North America

Get A Free Sample Click Here

Ovarian cancer is the deadly gynecological cancer and is the seventh most common cancer in women globally. Most women with ovarian cancer are diagnosed at the advanced stage, which is most challenging to treat. Chemotherapy and Surgery are usually used in the treatment of ovarian cancer.

Market Dynamics

The major driving forces are rising ovarian cancer incidence, a growing number of clinical trials for innovations, increasing health expenditure, the use of combination therapies to treat ovarian cancer, and an increasing geriatric population.

The increasing burden of ovarian cancer and the growing female geriatric population drive global market growth.

The growing prevalence and female geriatric population are fueling the global market growth. For instance, according to the World Cancer Research Fund International, ovarian cancer is the 8th most commonly occurring cancer in women and the 18th most common cancer overall. As per the NIH, there were more than 313,000 new cases of ovarian cancer in 2020, and a total of 207,252 new deaths from ovarian cancer were reported globally; ovarian carcinoma is the most common type of ovarian cancer, comprising over 90% of all ovarian cancer cases. Furthermore, according to the NIH, the risk of ovarian cancer increases in females with age; therefore, the growing female geriatric population drives the global market growth. For instance, 727 million persons aged 65 years or over in 2020. Since women live longer than men, they comprise the majority of older persons, especially at advanced ages.

The costly cancer treatment is restraining the global Ovarian Cancer growth.

However, the high cost of cancer treatment, lack of accurate diagnosis of ovarian cancer, and lack of awareness in emerging and low-income economies are expected to restrain the market. For patients without health insurance, the cost ranges from $20,000 to $200,000 or more for treatment with surgery and chemotherapy for advanced cancer.

Industry analysis.

The global ovarian cancer report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing, pipeline analysis Etc.

Segment Analysis

The imaging test market is expected to have a greater grasp of the Ovarian Cancer market during the forecast period (2022-2029)

Epithelial ovarian cancer dominated the global market in 2021. It is expected to show a similar trend throughout the forecast period (2022-2029), as epithelial cancer is the most common type of ovarian cancer. A large number of clinical research is ongoing. For instance, according to Cancer Research UK, about 90 out of 100 tumors of the ovary (90%) are epithelial, and according to the ClinicalTrails.Gov, over 200 interventional studies are active for epithelial ovarian cancer examples of a few are a phase III Randomized Study Evaluating Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for treatment of relapse ovarian cancer, a phase II pharmacological study with Wee-1 inhibitor MK-1775 combined with carboplatin in patients with p53 mutated epithelial ovarian cancer and early relapse (< 3 months) or progression during standard first-line treatment, a GINECO phase II trial for the assessment of safety and the efficacy of the Bevacizumab, Olaparib and Durvalumab (MEDI 4736) combination in patients with advanced epithelial ovarian cancer in relapse, a phase 3, single-arm study of Mirvetuximab Soravtansine in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression and many more.

Geographical Analysis

The Asia Pacific is expected to command dominating the global ovarian cancer market.

The Asia Pacific is predicted to command the global ovarian cancer market since the Asia Pacific has the highest prevalence of ovarian cancer and the largest portion of the global population. For instance, according to the statistics from the WHO, in 2020, Eastern Asia had 71 353 new cases and 45 690 deaths due to ovarian cancer, South-Eastern Asia had 31 169 new cases and 20 012 deaths because of ovarian cancer, South-Central Asia had 59 730 new cases and 41 407 deaths of ovarian cancer patients while Western Asia had 8 507 new cases and 5 827 deaths as a result of ovarian cancer advancement. Furthermore, the Asia Pacific has the highest populated countries in the world, India and China; for instance, in 2021, India's population was 1.412 billion, compared to China's 1.426 billion. The Asia Pacific accounts for 60% of the global population, fueling the ovarian cancer market growth in this region.

Competitive Landscape

The key players operating in the global ovarian cancer market are Roche, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Celgene, Amgen, Pfizer, and Merck. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the ovarian cancer market globally. For instance, on 16 August 2022, GSK acquired Affinivax, Inc. Also, on December 22, 2021, Novartis acquired Gyroscope Therapeutics.

AstraZeneca plc

Overview:

AstraZeneca plc is a leading pharmaceutical and biotechnology company dealing with oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. AstraZeneca plc was founded in 1999 and is headquartered in Cambridge, UK.

Product Portfolio:

The product portfolio of AstraZeneca plc for ovarian cancer has LYNPARZA.

The global ovarian cancer report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Frequently Asked Questions

What is the Projected CAGR value of the Ovarian Cancer Market?

Ovarian Cancer Market is expected to grow at a CAGR of 16% during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America region Controls the Ovarian Cancer Market during 2022-2029.

Which is the fastest growing region in the Ovarian Cancer Market?

Among all regions, Asia Pacific is the fastest growing market share during the forecast period.

Trending Topics

Endometrial Cancer Market

Skin Cancer Market